الفهرس 
AcknowledgmentOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
This study aimed to : Except for prolactinomas, microsurgery remains the primary treatment in surgically fit patients for sellar lesions, particularly so when the lesion is demonstrating mass effect on the optic apparatus or hormonal overproduction. Nevertheless, 20–50% of patients eventually demonstrate recurrence of their adenomas, and adjuvant treatment is often necessary for these patients. Stereotactic radiosurgery has been demonstrated to be a safe and highly effective treatment for patients with recurrent or residual pituitary adenomas. Radiosurgery affords effective growth control and hormonal normalization for patients with a generally shorter latency period than that of fractionated radiotherapy. This short latency period with radiosurgery can typically be managed with suppressive medications. Furthermore, the complications (e.g. radiation induced neoplasia, cerebral vasculopathy, etc.) associated with radiosurgery are infrequent. Radiosurgery may even serve as a primary treatment for those patients deemed unfit for microsurgical resection as a result of other comoribidities or with demonstrable tumors in a surgically inaccessible location. In the future, radiosurgery will yield even better results. The introduction of technical advances such as the Gamma Knife Perfexion, incorporation of new neuro-imaging technologies into dose planning, and improvements in the shielding techniques of radiosurgical units will provide improved conformity and steeper dose fall-off. Long-term periodic neurological, neuro-imaging, and endocrinological follow-up of patients must be performed to assess for delayed complications or tumor recurrence. Finally, physicians caring for \pituitary patients should establish uniform endocrinological criteria and diagnostic testing for pre and post-radiosurgical evaluations.